Cinnamoyl-piperazine derivatives and their use as par-1...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 295/18 (2006.01) A61K 31/4965 (2006.01) A61P 9/00 (2006.01)

Patent

CA 2655527

The present invention relates to compounds of general formula (I), wherein: R1 represents halogen, CN or NO2; R2 represents hydrogen or halogen; n represents 1 or 2; R3 represents phenyl substituted by one or more halogens or C1-C6 alkyls; or a cyclohexyl; as well as the therapeutically-acceptable salts or solvates thereof. These compounds are useful as protease-activated receptor-1 (par-1) antagonists, particularly in the treatment of thrombosis.

L'invention concerne des composés de la formule générale (I), dans laquelle R1 représente: halogène, CN ou NO2; R2 représente: hydrogène ou halogène; n représente: 1 ou 2; R3 représente: phényle substitué par un ou plusieurs halogènes ou C1-C6 alkyle; ou un cyclohexyle; et des sels ou solvates thérapeutiquement acceptables de ces derniers. Les composés de l'invention sont utilisés comme antagonistes du récepteur 1 activé par la protéase ("protease-activated receptor-1" ou PAR-1), en particulier dans le traitement de la thrombose.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cinnamoyl-piperazine derivatives and their use as par-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cinnamoyl-piperazine derivatives and their use as par-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cinnamoyl-piperazine derivatives and their use as par-1... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1446980

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.